Download Library

Download Library

Document Type
Full Year 2016 Results Podcast
Full Year 2016 Results Podcast
Cost-effective Analysis of Ofatumumab for Relapsed CLL - ASH poster - December 2016 (Tremblay)
Cost-effective Analysis of Ofatumumab for Relapsed CLL - ASH poster - December 2016 (Tremblay)
Results of an Early Access Treatment Protocol of Daratumumab with Relapsed or Refractory MM - ASH poster - December 2016 (Chari)
Results of an Early Access Treatment Protocol of Daratumumab with Relapsed or Refractory MM - ASH poster - December 2016 (Chari)
Efficacy of DRd Versus Rd in Relapsed or Refractory MM Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux - ASH presentation - December 2016 (Usmani)
Efficacy of DRd Versus Rd in Relapsed or Refractory MM Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux - ASH presentation - December 2016 (Usmani)
Use of Montelukast to Reduce Infusion Reactions in an Early Access Program (EAP) of Daratumumab in United States Patients With Relapsed or Refractory Multiple Myeloma - ASH Poster - December 2016 (Chari)
Use of Montelukast to Reduce Infusion Reactions in an Early Access Program (EAP) of Daratumumab in United States Patients With Relapsed or Refractory Multiple Myeloma - ASH Poster - December 2016 (Chari)
Evaluation of MRD in Relapsed/Refractory MM Patients Treated with Daratumumab in Combination with Rd or Vd - ASH presentation - December 2016 (Avet-Loiseau)
Evaluation of MRD in Relapsed/Refractory MM Patients Treated with Daratumumab in Combination with Rd or Vd - ASH presentation - December 2016 (Avet-Loiseau)
High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory MM Pts Treated with Daratumumab Supports Immune Modulation As a Novel Mechanism of Action - ASH poster - December 2016 (Adams)
High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory MM Pts Treated with Daratumumab Supports Immune Modulation As a Novel Mechanism of Action - ASH poster - December 2016 (Adams)
Overcoming the interference of daratumumab with Immunofixation Electrophoresis using an industry-developed DIRA test - ASH poster - December 2016 (Irimia)
Overcoming the interference of daratumumab with Immunofixation Electrophoresis using an industry-developed DIRA test - ASH poster - December 2016 (Irimia)
Population Pharmacokinetic and Exposure-Response Analyses for Daratumumab in Combination Therapies for Patients with MM Who Have Received 1 or More Prior Lines of Therapy - ASH poster - December 2016 (Xu)
Population Pharmacokinetic and Exposure-Response Analyses for Daratumumab in Combination Therapies for Patients with MM Who Have Received 1 or More Prior Lines of Therapy - ASH poster - December 2016 (Xu)
Genmab's ASH 2016 Data Review Meeting, San Diego, CA - December 2016
Genmab's ASH 2016 Data Review Meeting, San Diego, CA - December 2016
Potentiation of Anti-Myeloma Activity of Daratumumab with Combination of Cyclophosphamide, Lenalidomide or Bortezomib Via a Tumor Secretory Response That Greatly Augments Macrophage- Induced ADCP - ASH poster - December 2016 (Rigalou)
Potentiation of Anti-Myeloma Activity of Daratumumab with Combination of Cyclophosphamide, Lenalidomide or Bortezomib Via a Tumor Secretory Response That Greatly Augments Macrophage- Induced ADCP - ASH poster - December 2016 (Rigalou)
Phase 1b Study to Assess Subcutaneous Daratumumab in pts with Relapsed or Refractory MM (PAVO) - ASH presentation - December 2016 (Usmani)
Phase 1b Study to Assess Subcutaneous Daratumumab in pts with Relapsed or Refractory MM (PAVO) - ASH presentation - December 2016 (Usmani)
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Based on Prior Treatment Exposure: Updated Efficacy Analysis of CASTOR - ASH Poster - December 2016 (Chanan-Khan)
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Based on Prior Treatment Exposure: Updated Efficacy Analysis of CASTOR - ASH Poster - December 2016 (Chanan-Khan)
Comparative Effectiveness of Daratumumab Versus a Real-World Historical Control in Heavily Pretreated and Highly Refractory MM - ASH poster - December 2016 (Hájek)
Comparative Effectiveness of Daratumumab Versus a Real-World Historical Control in Heavily Pretreated and Highly Refractory MM - ASH poster - December 2016 (Hájek)
Jefferies London Healthcare Conference, London, UK - November 2016
Jefferies London Healthcare Conference, London, UK - November 2016
Interim Report for the Nine Months Ended September 30, 2016
Interim Report for the Nine Months Ended September 30, 2016
Daratumumab in combination with Dexamethasone in Resistant or Refractory MM - ASH abstract - November 2016 (Boyle)
Daratumumab in combination with Dexamethasone in Resistant or Refractory MM - ASH abstract - November 2016 (Boyle)
Efficacy of DRd Versus Rd for Relapsed or Refractory MM: Updated Analysis of Pollux - ASH abstract - November 2016 (Moreau)
Efficacy of DRd Versus Rd for Relapsed or Refractory MM: Updated Analysis of Pollux - ASH abstract - November 2016 (Moreau)
Overcoming the interference of daratumumab with Immunofixation Electrophoresis using an industry-developed DIRA test - ASH abstract - November 2016 (Caillon)
Overcoming the interference of daratumumab with Immunofixation Electrophoresis using an industry-developed DIRA test - ASH abstract - November 2016 (Caillon)
Cost-Effectiveness Analysis of Ofatumumab as a Treatment for Relapsed CLL in the United States - ASH abstract - November 2016 (Tremblay)
Cost-Effectiveness Analysis of Ofatumumab as a Treatment for Relapsed CLL in the United States - ASH abstract - November 2016 (Tremblay)
Comparative Effectiveness of Daratumumab Versus a Real-World Historical Control in Heavily Pretreated and Highly Refractory MM - ASH abstract - November 2016 (Hájek)
Comparative Effectiveness of Daratumumab Versus a Real-World Historical Control in Heavily Pretreated and Highly Refractory MM - ASH abstract - November 2016 (Hájek)
Clinical Efficacy of Daratumumab, Pomalidomide & Dexamethasone in Relapsed, Refractory Myeloma: Utility of Retreatment with Daratumumab Among Refractory Patients - ASH abstract - November 2016 (Nooka)
Clinical Efficacy of Daratumumab, Pomalidomide & Dexamethasone in Relapsed, Refractory Myeloma: Utility of Retreatment with Daratumumab Among Refractory Patients - ASH abstract - November 2016 (Nooka)
Phase 1b Study to Assess Subcutaneous Daratumumab in pts with Relapsed or Refractory MM (PAVO) - ASH abstract - November 2016 (Usmani)
Phase 1b Study to Assess Subcutaneous Daratumumab in pts with Relapsed or Refractory MM (PAVO) - ASH abstract - November 2016 (Usmani)
Use of Montelukast to Reduce Infusion Reactions in an Early Access Treatment Protocol of Daratumumab with Relapsed or Refractory MM - ASH abstract - November 2016 (Chari)
Use of Montelukast to Reduce Infusion Reactions in an Early Access Treatment Protocol of Daratumumab with Relapsed or Refractory MM - ASH abstract - November 2016 (Chari)
Efficacy of DVd Versus Vd in Relapsed or Refractory Myeloma Based on Prior Lines of Therapy: Updated Analysis of Castor - ASH abstract - November 2016 (Mateos)
Efficacy of DVd Versus Vd in Relapsed or Refractory Myeloma Based on Prior Lines of Therapy: Updated Analysis of Castor - ASH abstract - November 2016 (Mateos)
Evaluation of MRD in Relapsed/Refractory MM Patients Treated with Daratumumab in Combination with Rd or Vd - ASH abstract - November 2016 (Avet-Loiseau)
Evaluation of MRD in Relapsed/Refractory MM Patients Treated with Daratumumab in Combination with Rd or Vd - ASH abstract - November 2016 (Avet-Loiseau)